Ongoing low-dose maintenance (experimental) Continuous dosing approach: Dose: 1-2mg daily OR 3-5mg 2-3x weekly Duration: Ongoing (not cycled) Goal: Maintain constant telomerase activation Status: Experimental, not from research protocols Rationale: Telomerase needs continuous activation to maintain telomere length Cyclic dosing may allow regression between cycles Low-dose continuous might provide stable benefits Similar to maintenance protocols for other peptides Continuous dosing options: Advantages of continuous: No "off" periods where benefits regress Potentially stronger cumulative anti-aging More like natural physiologic regulation Easier to stack with other peptides Disadvantages: Much higher annual cost ($1,800-3,600 vs $300-600) No long-term safety data Uncertain if better than cyclic approach Storage challenges (more reconstitution) Deviates from proven protocols Current recommendation: Stick with proven 10-day cycles for most users Consider continuous only if cyclic approach inadequate Start with standard protocol first Assess your individual response Consult with peptide-knowledgeable physician Use our peptide cycle planning guide to design your Epithalon protocol

The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health. Oxidative Medicine and Cellular Longevity
BPC-157 has shown localized effects on tendon, ligament and gut tissue and strong pro-angiogenic activity in preclinical models[1]
Therefore, although our review aimed to broaden our knowledge on the clinical applications of ALA, further randomized, double-blind, placebo-controlled clinical trials with adequate sample sizes, homogeneity of population studied, statistical power, as well as longer duration are (still) needed to confirm the clinical benefit of this multifunctional compound and extend its use in routine medical practice
For peptides cleared by the kidney, check creatinine and estimated glomerular filtration rate (eGFR) more often